Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Prior Auth Durations | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Authorization Duration Exception-REG

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs minimum prescription drug prior authorization durations for qualifying criteria in Illinois, New Jersey, New York, Oklahoma, Texas, and Virginia, including initial and continued authorization.

    Policy Summary
    PayerOscar Health
    PolicyAuthorization Duration Exception-REG
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the prescription drug prior authorization request with the treatment duration when known.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6States covered
    6 monthsShortest minimum duration
    36 monthsLongest minimum duration
    Initial and continuedAuthorization stages
    Up to 12 monthsIllinois requested duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 years
    Oklahoma chronic-drug duration

    State-Specific Coverage Criteria

    Illinois healthcare professional-requested duration

    For an Illinois plan, authorize the requested treatment duration when specified.

    Illinois provider-requested duration: The member's plan is issued for Illinois and the healthcare professional has requested a treatment duration for the prescription drug.Up to 12 months

    Applies to initial review or continued care. If no duration is specified, apply the applicable Illinois chronic or non-chronic criteria.

    Illinois acute or non-chronic conditions

    Covered for at least six months when ALL criteria are met.

    Illinois acute or non-chronic condition: The member's plan is issued for Illinois; the prescription drug is prescribed to treat a non-chronic condition; and the prescription drug is not a benzodiazepine or Schedule II narcotic drug.At least 6 months

    Authorize for six months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. For an acute condition, use the guideline duration when it aligns with the drug's prescribing information.

    Illinois chronic conditions

    Covered for at least 12 months when ALL criteria are met.

    Illinois chronic condition: The member's plan is issued for Illinois; the prescription drug is prescribed to treat a chronic or long-term condition; and the prescription drug is not a benzodiazepine or Schedule II narcotic drug.At least 12 months

    Authorize for 12 months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. For a one-time treatment or other specified duration, use the guideline duration when it aligns with the prescribing information.

    New Jersey chronic conditions

    Covered for at least six months when ALL criteria are met.

    New Jersey chronic condition: The member's plan is issued for New Jersey and the prescription drug is prescribed to treat a chronic or long-term condition.At least 6 months

    Authorize for six months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. For a one-time treatment or other specified duration, use the guideline duration when it aligns with the prescribing information.

    New York chronic conditions

    Covered for at least 12 months when ALL criteria are met.

    New York chronic outpatient treatment: The member's plan is issued for New York; the prescription drug is prescribed to treat a chronic health condition; the request is for an outpatient course of treatment; and the provider has not recommended a change to the course of treatment.At least 12 months

    Authorize for 12 months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. For a one-time treatment or other specified duration, use the guideline duration when it aligns with the prescribing information.

    Oklahoma chronic conditions

    Covered for at least 36 months when ALL criteria are met.

    Oklahoma chronic formulary drug: The member's plan is issued for Oklahoma; the prescription drug treats a chronic condition; the prescription drug is on the formulary; the member remains on the same health plan; and the drug is not an opioid, is not a controlled substance prohibited from being dispensed without a prescription under federal law, and is not prescribed for weight loss.At least 36 months

    The authorization remains valid for three years unless clinical criteria change, the requested generic is removed from the formulary, or the drug moves to a less preferred formulary tier. A longer guideline duration may apply; for a one-time treatment or other specified duration, use the guideline duration when aligned with prescribing information.

    Texas autoimmune disease, hemophilia, or von Willebrand disease

    Covered for at least 12 months when ALL criteria are met.

    Texas qualifying condition and drug: The member is a resident of Texas; the prescription drug is prescribed to treat autoimmune disease, hemophilia, or von Willebrand disease; and the drug is not an opioid, benzodiazepine, barbiturate, or carisoprodol; does not typically require treatment for less than 12 months; does not have an FDA boxed warning for use requiring specific provider assessment; and is not used outside the FDA-approved indication.At least 12 months

    Authorize for 12 months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline.

    Virginia initial authorization

    Covered for at least six months for initial authorization when ALL criteria are met.

    Virginia initial authorization: The member's plan is issued for Virginia; there is no evidence of fraud or misrepresentation; no final FDA, regulatory, or manufacturer action affects the drug's safety, efficacy, market availability, or use; no additional safety or efficacy monitoring is clinically appropriate or recommended; no prescribed drug combination would cause an interaction; and no generic or biosimilar of the requested product has been added to the formulary.At least 6 months

    Authorize for six months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. Use the guideline duration when it aligns with the prescribing information.

    Virginia continued authorization

    Covered for at least 12 months for continued care when ALL criteria are met.

    Virginia continued authorization: The member's plan is issued for Virginia; there is no evidence of fraud or misrepresentation; no final FDA, regulatory, or manufacturer action affects the drug's safety, efficacy, market availability, or use; no additional safety or efficacy monitoring is clinically appropriate or recommended; no prescribed drug combination would cause an interaction; and no generic or biosimilar of the requested product has been added to the formulary.At least 12 months

    Authorize for 12 months or the longer duration specified by the applicable class-, drug-, or indication-specific clinical guideline. Use the guideline duration when it aligns with the prescribing information.

    Illinois authorization duration

    Apply the duration corresponding to the type of Illinois authorization.

    • General authorization: The authorization is valid for the lesser of six months after the provider receives approval or the treatment length determined by the treating professional or plan renewal.6 months maximum

      The approval remains effective despite prescription-drug dosage changes; dosage increases must meet established evidentiary standards and safety edits may apply.

    • Recurring or maintenance chronic-care authorization: The authorization is valid for the lesser of 12 months after the provider receives approval or the treatment length determined by the treating professional for a recurring healthcare service or maintenance medication treating a chronic or long-term condition.12 months maximum

    New Jersey chronic-care authorization

    Apply the New Jersey chronic-care authorization period.

    New Jersey chronic-care duration: The authorization for a healthcare service treating a chronic or long-term care condition remains valid for 180 days.180 days

    A shorter period may be used when necessary to monitor patient safety or treatment effectiveness, with notice to the treating provider.

    New York annual review limit

    Limit utilization review for the approved outpatient chronic-care course.

    New York utilization review frequency: Do not conduct utilization review more than once per year for an outpatient course of treatment for a chronic health condition, measured from the preauthorization approval date.No more than once per year

    Review may occur for a new course of treatment when the attending provider recommends a change. New treatment, testing, or procedures outside the approved course may require separate preauthorization.

    Oklahoma chronic-drug authorization

    Apply the Oklahoma chronic-condition prescription-drug authorization period.

    Oklahoma chronic-drug duration: The prescription drug treats a chronic condition, prior authorization is required, and the enrollee remains on the same health plan.3 years

    Keep the authorization valid for three years from the date the provider receives approval, subject to changes in clinical criteria, removal of the requested generic from the formulary, or movement of the drug to a less preferred formulary tier.

    Texas annual prescription-drug authorization

    Limit annual prior authorization for specified Texas treatments.

    Texas annual authorization limit: The prescription drug is prescribed to treat an autoimmune disease, hemophilia, or von Willebrand disease.No more than 1 annually

    The limit is subject to exclusions for opioids, benzodiazepines, barbiturates, carisoprodol, drugs with treatment periods shorter than 12 months, certain FDA-boxed-warning drugs requiring specific provider assessment, and use outside the FDA-approved indication.

    Virginia initial and continued authorization

    Maintain an approved Virginia prescription-drug authorization for the applicable minimum duration.

    Virginia minimum duration: The approved prescription drug has been scheduled, provided, or delivered consistently with the authorization.Initial: at least 6 months; continued: at least 12 months

    The authorization may be revoked, limited, conditioned, modified, or restricted only for specified fraud, regulatory or manufacturer action, monitoring, interaction, or formulary circumstances. This rule does not require coverage of an otherwise noncovered benefit or coverage after plan enrollment ends.

    For Illinois, the minimum authorization-duration rules do not apply to benzodiazepines or Schedule II narcotic drugs. For qualifying non-chronic conditions, the standard minimum is 6 months; for qualifying chronic or long-term conditions, the standard minimum is 12 months.

    The Oklahoma 36-month authorization duration applies only to qualifying formulary drugs used for chronic conditions. It does not apply to opioids, controlled substances prohibited from dispensing without a prescription under federal law, or prescription drugs used for weight loss.

    The Texas 12-month authorization duration does not apply to opioids, benzodiazepines, barbiturates, or carisoprodol. It also excludes prescription drugs with a typical treatment period of less than 12 months, certain FDA boxed-warning drugs requiring specific provider assessment, and FDA-approved drugs used outside the approved indication.

    Virginia minimum authorization durations require that the authorization was not obtained through fraud or misrepresentation; that no relevant FDA, regulatory, or manufacturer action affects the drug’s safety, efficacy, market availability, or use; and that no additional safety or efficacy monitoring is recommended. The duration exceptions also apply when a drug interaction exists or a generic or biosimilar has been added to the formulary.

    Illinois authorization-duration provisions do not apply to benzodiazepines or Schedule II narcotic drugs, including opioids. This exclusion applies to both the general 6-month authorization rule and the 12-month rule for recurring services or maintenance medications used for chronic or long-term conditions.

    The Oklahoma three-year prior authorization provision does not apply to opioids, controlled substances prohibited from dispensing without a prescription under federal law, or prescription drugs used for weight loss. The authorization may also be affected if clinical criteria change, the requested generic is removed from the formulary, or the drug moves to a less preferred formulary tier.

    Texas limits prior authorization to no more than once annually for qualifying drugs used to treat autoimmune disease, hemophilia, or von Willebrand disease. The limit does not apply to opioids, benzodiazepines, barbiturates, carisoprodol, drugs with treatment periods shorter than 12 months, certain FDA boxed-warning drugs requiring specific provider assessment, or FDA-approved drugs used outside the approved indication.

    Authorization Submission and Operational Rules

    Documentation Required

    Submit Treatment Duration

    Submit the requested treatment duration with each prior authorization request when the duration is known. If no duration is specified, apply the applicable state-specific chronic or non-chronic condition rules and any stated exceptions.

    • The requested duration may be up to 12 months where permitted by the applicable rule.
    • Apply the duration determined by the member’s health care professional, the prescribing information, and applicable state requirements.
    Prior Authorization

    Apply the Longer Guideline Duration

    When a state minimum duration applies, use the longer duration required by the applicable class-, drug-, or indication-specific clinical guideline. Apply the guideline duration when it is longer than the statutory or policy minimum, including when the drug’s prescribing information specifies a compatible one-time or other treatment duration.

    Policy Background

    This policy addresses the administrative and regulatory duration of prescription drug prior authorizations, not the clinical appropriateness of a particular drug. Minimum durations vary by state, authorization stage, condition type, drug class, formulary status, and safety or monitoring considerations. A class-, drug-, or indication-specific clinical guideline may require a longer duration, while prescribing information may require a shorter or otherwise specified duration for a one-time or time-limited treatment.

    Defined Terms

    Acute Condition
    OnsetSudden in onset
    CourseSelf-limiting and generally resolves in days or weeks
    Untreated riskMay lead to a chronic condition if untreated
    Chronic Condition
    DevelopmentDevelops over a long period
    PatternGenerally persistent or recurring
    DurationMeasured in months and years

    Initial Authorization Criteria

    State-specific initial authorization durations

    For initial review, apply the state-specific criteria and minimum authorization duration.

    State-specific initial authorization: Illinois: authorize the healthcare professional-requested duration up to 12 months, or at least 6 months for qualifying non-chronic treatment or at least 12 months for qualifying chronic treatment; New Jersey: at least 6 months for qualifying chronic treatment; New York: at least 12 months for qualifying chronic outpatient treatment; Oklahoma: at least 36 months for qualifying chronic formulary treatment; Texas: at least 12 months for qualifying autoimmune disease, hemophilia, or von Willebrand disease treatment; Virginia: at least 6 months when initial-authorization criteria are met.6, 12, or 36 months depending on state and criteria

    A longer class-, drug-, or indication-specific guideline duration may apply.

    Continued Authorization Criteria

    State-specific continued authorization durations

    For continued care, apply the state-specific criteria and minimum authorization duration.

    State-specific continued authorization: Illinois: authorize the healthcare professional-requested duration up to 12 months, or at least 6 months for qualifying non-chronic treatment or at least 12 months for qualifying chronic treatment; New Jersey: at least 6 months for qualifying chronic treatment; New York: at least 12 months for qualifying chronic outpatient treatment; Oklahoma: at least 36 months for qualifying chronic formulary treatment; Texas: at least 12 months for qualifying autoimmune disease, hemophilia, or von Willebrand disease treatment; Virginia: at least 12 months when continued-authorization criteria are met.6, 12, or 36 months depending on state and criteria

    A longer class-, drug-, or indication-specific guideline duration may apply.

    Virginia continued therapy

    Apply the Virginia continued prescription-drug authorization duration.

    Virginia continued authorization duration:

    Site-of-Care Applicability

    Billing Rule

    Confirm the New York outpatient course of treatment

    The New York 12-month duration applies when the request is for an outpatient course of treatment for a chronic health condition.

    Generic and Biosimilar Restrictions

    Denial Risk

    Check for a formulary generic or biosimilar

    For Virginia initial or continued authorization duration criteria, confirm that no generic or biosimilar of the requested product has been added to the prescription drug formulary.

    Policy Summary
    PayerOscar Health
    PolicyAuthorization Duration Exception-REG
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the prescription drug prior authorization request with the treatment duration when known.
    SourceLink
    On This Page
    State-Specific Coverage CriteriaAuthorization Submission and Operational RulesPolicy BackgroundDefined TermsInitial Authorization CriteriaContinued Authorization CriteriaSite-of-Care ApplicabilityGeneric and Biosimilar Restrictions
  1. This longer-duration rule applies to applicable Illinois, New Jersey, New York, Oklahoma, Texas, and Virginia authorizations.
  2. For acute or chronic conditions, use the clinical-guideline duration when it aligns with the drug’s prescribing information.
  3. Billing Rule

    Illinois General Authorization Duration

    For an Illinois plan, a prior authorization approval is valid for the lesser of six months after the health care professional or provider receives approval, the length of treatment determined by the patient’s health care professional, or renewal of the plan. The approval period remains effective despite changes, including prescription-drug dosage changes, subject to established evidentiary standards and safety edits.

    • The rule does not apply to benzodiazepines or Schedule II narcotic drugs, including opioids.
    • The approval period is subject to the applicable treatment-duration and plan-renewal limits.
    Prior Authorization

    Illinois Chronic-Condition Duration

    For an Illinois recurring health care service or maintenance medication used to treat a chronic or long-term condition, the authorization remains valid for the lesser of 12 months from receipt of approval or the length of treatment determined by the patient’s health care professional.

    • The rule applies when prior authorization is required for the recurring service or maintenance medication.
    • The rule does not apply to benzodiazepines or Schedule II narcotic drugs, including opioids.
    Prior Authorization

    New Jersey Chronic-Care Duration

    For a New Jersey chronic or long-term care condition, a prior authorization remains valid for 180 days, and the payer may not require the covered person to obtain another authorization for the same health care service during that period.

    • The rule applies to required prior authorization for a health care service treating a chronic or long-term care condition.
    • Apply the applicable treatment-duration and clinical-guideline rules when they provide a longer duration.
    Prior Authorization

    New York Annual Utilization Review

    For a qualifying New York outpatient course of treatment for a chronic health condition, utilization review may not occur more than once per year from the date of pre-authorization approval unless the enrollee’s attending provider recommends a change to the course of treatment.

    • A chronic health condition is expected to last at least one year and requires ongoing treatment to manage the condition or prevent an adverse health event.
    • New treatment, testing, or procedures not included in the approved course may require separate pre-authorization.
    Prior Authorization

    Oklahoma Chronic-Drug Duration

    For an Oklahoma chronic-condition prescription drug, the prior authorization remains valid for three years from the date the provider receives approval when the enrollee remains on the same health plan and the applicable formulary and drug criteria are satisfied.

    • The three-year period applies to a formulary drug prescribed for a chronic condition.
    • Use the longer applicable class-, drug-, or indication-specific clinical-guideline duration when required.
    Prior Authorization

    Texas Annual Prior Authorization Limit

    For a Texas prescription drug prescribed to treat an autoimmune disease, hemophilia, or Von Willebrand disease, do not require more than one prior authorization annually for the prescription drug benefit when the statutory criteria are met.

    • The annual limit applies to a qualifying Texas resident and prescription drug.
    • The authorization may provide at least 12 months, or the longer duration required by the applicable clinical guideline.
    Prior Authorization

    Virginia Minimum Authorization Duration

    For a Virginia prescription-drug authorization, provide at least six months for an initial authorization and at least 12 months for continued authorization when the applicable conditions are met.

    • The member must have a Virginia plan and meet the applicable authorization requirements.
    • Use the longer duration required by the applicable clinical guideline when applicable.

    Unsupported block type: documentation

    Denial Risk

    Illinois Acute or Non-Chronic Drug Exclusion

    The Illinois six-month minimum for acute or non-chronic prescription-drug treatment does not apply when the drug is a benzodiazepine or Schedule II narcotic drug.

    • The non-chronic-condition criteria otherwise require an Illinois plan and treatment of a non-chronic condition.
    • When the drug’s prescribing information and applicable clinical guideline specify an aligned duration, use the guideline duration.
    Denial Risk

    Illinois Chronic-Drug Exclusion

    The Illinois 12-month minimum for chronic or long-term prescription-drug treatment does not apply when the drug is a benzodiazepine or Schedule II narcotic drug.

    • The chronic-condition criteria otherwise require an Illinois plan and treatment of a chronic or long-term condition.
    • A one-time or other specified duration may apply when aligned with the prescribing information and clinical guideline.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Oklahoma Authorization Termination Events

    An Oklahoma three-year chronic-drug authorization may end before three years if the applicable termination event occurs.

    • Clinical criteria for the requested drug’s prior authorization change.
    • The plan removes the requested generic prescription drug from the formulary.
    • The plan moves the requested prescription drug to a less preferred formulary tier.
    Prior Authorization

    Oklahoma Duration Exceptions

    The Oklahoma 36-month duration is subject to the applicable clinical-criteria, formulary, treatment, and prescribing-information exceptions. Apply the duration required by the relevant clinical guideline when it is longer or when the prescribing information specifies an aligned one-time or other treatment duration.

    • The authorization requires continued enrollment in the same health plan and satisfaction of the formulary and qualifying-drug criteria.
    • The statutory duration does not override the listed opioid, controlled-substance, or weight-loss exclusions.
    Denial Risk

    Virginia Authorization Restrictions

    For an approved Virginia prescription-drug authorization, do not revoke, limit, condition, modify, or restrict the authorization during its applicable duration unless a listed exception permits the action.

    • Permitted exceptions include fraud or misrepresentation; FDA, regulatory, or manufacturer action affecting market availability, use, safety, or efficacy; additional safety or efficacy monitoring; a drug interaction; or addition of a generic or biosimilar to the formulary.
    • The authorization must otherwise remain in force for at least six months initially and 12 months for continued authorization.
    • The restriction does not require coverage of an otherwise non-covered benefit or coverage after the enrollee is no longer covered.
    Drug
    RecognitionA substance recognized by an official pharmacopoeia or formulary
    Intended usesMay diagnose, cure, mitigate, treat, or prevent disease
    ScopeMay affect body structure or function, serve as a component of a medicine, and include biological products
    Boxed warning or Black box warning
    Safety levelThe highest safety-related warning assigned to a drug by the FDA
    PurposeDraws attention to major risks of the drug
    LocationAppears on the FDA label
    Hemophilia
    ConditionA bleeding disorder in which the blood does not clot properly
    Hemophilia AClassic hemophilia caused by factor VIII deficiency
    Hemophilia B and CHemophilia B involves factor IX deficiency; Hemophilia C involves factor XI deficiency
    Von Willebrand Disease
    ConditionA bleeding disorder in which the blood does not clot properly
    CauseLow levels of von Willebrand factor in the blood
    Alternative causeThe von Willebrand factor protein does not work properly
    Autoimmune Disease
    DefinitionA condition in which the body's immune system attacks and destroys healthy body tissue by mistake
    ExamplesExamples include Crohn's disease, multiple sclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis, lupus, type 1 diabetes, and ulcerative colitis
    Affected tissueHealthy body tissue is mistakenly targeted by the immune system
    Pharmacy benefit drugs
    How obtainedPicked up at a drugstore or sent by mail order
    ExamplesExamples include oral antibiotics and antihypertensives
    Benefit overlapSome drugs may be covered by either the pharmacy benefit or a medical benefit, including vaccines and drugs given by subcutaneous injection
    Medical benefit drugs
    AdministrationGiven by a healthcare provider in a healthcare setting
    ExamplesExamples include intravenous chemotherapy or immunotherapy infusions
    Benefit overlapSome drugs may be covered by either the medical benefit or a pharmacy benefit, including vaccines and drugs given by subcutaneous injection
    Chronic health condition
    Expected durationA condition expected to last at least one year
    Treatment needRequires ongoing treatment
    Treatment purposeOngoing treatment manages the condition effectively or prevents an adverse health event
    Chronic condition
    DurationA condition lasting one year or more
    Ongoing careRequires ongoing medical attention
    Daily activitiesMay limit activities of daily living
    Prior authorization
    ProcessA payer process for determining medical necessity
    Covered serviceApplies to an otherwise covered service
    Timing and scopeOccurs before the service is rendered and may include preadmission review, pretreatment review, utilization review, case management, or required advance notification
    The approved prescription drug has been scheduled, provided, or delivered consistently with the authorization.
    At least 12 months

    Specified fraud, safety, efficacy, regulatory, manufacturer, monitoring, interaction, or formulary circumstances may permit restriction or modification.

    Oklahoma continuation therapy

    Apply the Oklahoma continuation period when the member remains on the same plan.

    Oklahoma same-plan continuation: The prescription drug treats a chronic condition, prior authorization is required, and the enrollee remains on the same health plan.3 years

    Clinical-criteria or formulary changes may affect the authorization duration.